Microbot Medical's (MBOT) Buy Rating Reaffirmed at HC Wainwright

Key Points

• Microbot Medical's stock has a "buy" rating reaffirmed by HC Wainwright, with a price target of $12.00, suggesting a potential upside of 316.67% from its previous close.
• Various analysts have issued differing ratings: while Zacks has downgraded it to "hold," Wall Street Zen upgraded it from "sell" to "hold," reflecting a mixed sentiment in the market.
• The company recently reported a quarterly loss, missing consensus estimates, contributing to an average rating of "hold" from analysts, with expectations of -0.71 EPS for the current year.

Microbot Medical (NASDAQ:MBOT - Get Free Report)'s stock had its "buy" rating reaffirmed by research analysts at HC Wainwright in a report issued on Wednesday,Benzinga reports. They presently have a $12.00 price target on the biotechnology company's stock. HC Wainwright's price target would suggest a potential upside of 316.67% from the stock's previous close.

Several other analysts also recently commented on MBOT. Zacks Research downgraded shares of Microbot Medical from a "strong-buy" rating to a "hold" rating in a report on Thursday, August 21st. Wall Street Zen raised shares of Microbot Medical from a "sell" rating to a "hold" rating in a report on Friday, October 3rd. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Microbot Medical in a report on Wednesday, October 8th. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Hold" and an average target price of $12.00.

Microbot Medical Price Performance

Microbot Medical stock opened at $2.88 on Wednesday. The firm has a market capitalization of $152.05 million, a PE ratio of -4.97 and a beta of 1.25. The company's 50-day moving average is $3.39 and its 200-day moving average is $2.76. Microbot Medical has a fifty-two week low of $0.88 and a fifty-two week high of $4.67.

Microbot Medical (NASDAQ:MBOT - Get Free Report) last released its quarterly earnings data on Tuesday, August 12th. The biotechnology company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.02). As a group, analysts expect that Microbot Medical will post -0.71 EPS for the current year.

Hedge Funds Weigh In On Microbot Medical

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. U.S. Capital Wealth Advisors LLC bought a new position in Microbot Medical in the 2nd quarter valued at approximately $25,000. American Century Companies Inc. bought a new position in shares of Microbot Medical during the second quarter valued at about $32,000. Beacon Capital Management LLC lifted its position in shares of Microbot Medical by 166.7% during the second quarter. Beacon Capital Management LLC now owns 16,000 shares of the biotechnology company's stock valued at $40,000 after purchasing an additional 10,000 shares in the last quarter. XTX Topco Ltd bought a new position in shares of Microbot Medical during the second quarter valued at about $43,000. Finally, Lazari Capital Management Inc. bought a new position in shares of Microbot Medical during the second quarter valued at about $54,000. Institutional investors own 16.30% of the company's stock.

Microbot Medical Company Profile

Microbot Medical Inc, a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.